Integra LifeSciences (NASDAQ:IART) Hits New 12-Month Low – What’s Next?

Integra LifeSciences Holdings Corporation (NASDAQ:IART) shares hit a new 52-week low during mid-day trading on Friday . The company traded as low as $10.60 and last traded at $11.33, with a volume of 1253512 shares trading hands. The stock had previously closed at $11.59.

Key Headlines Impacting Integra LifeSciences

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Beat on the headline numbers — adjusted EPS of $0.83 (vs. $0.79 consensus) and revenue of $434.9M (above ~$429.6M est.), driven by strength in the Codman Specialty Surgical segment. This gives some near‑term comfort on core surgical franchise performance. Integra LifeSciences (NASDAQ:IART) Surprises With Q4 CY2025 Sales
• Positive Sentiment: Analyst/coverage notes highlighted the quarter beat on both EPS and revenue, reinforcing that adjusted profitability and segment growth (neurosurgery, instruments, ENT) remain intact even as some product lines recover. Integra LifeSciences (IART) Beats Q4 Earnings and Revenue Estimates
• Neutral Sentiment: Management hosted an earnings call and provided the slide deck — useful for color on remediation progress, operational changes and the $25–$30M cost savings target for 2026 (simplified operating model). Listen/read the transcript for Q&A. Q4 2025 Earnings Call Transcript
• Neutral Sentiment: The company reiterated remediation and compliance progress (supply reliability improvements, product relaunches) which are operationally constructive but longer‑dated in impact. Press Release / 2025 Results & 2026 Guidance
• Negative Sentiment: Guidance disappointed near term — Q1 2026 adjusted EPS guide $0.37–$0.45 vs ~ $0.47 consensus, and Q1 revenue guide $375–$390M below the ~$393M street view. The softer Q1 guide is the main driver of the share decline. Integra beats estimates but guides below consensus
• Negative Sentiment: Balance‑sheet and cash concerns: net debt (~$1.6B), leverage ~4.5x, weak free cash flow conversion for 2025, and capital spending pressure — these constrain flexibility and amplify investor sensitivity to any misses. QuiverQuant summary of results
• Negative Sentiment: Large non‑cash items and legacy issues remain headline risks: FY2025 GAAP net loss driven by a $511M goodwill impairment and ongoing remediation/recall‑related charges — these limit the usefulness of GAAP EPS and keep upside tied to execution. Guidance also excludes potential tariff recoveries, adding uncertainty. MSN coverage: why stock trades down

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on IART. Weiss Ratings restated a “sell (e+)” rating on shares of Integra LifeSciences in a research report on Monday, December 29th. Wall Street Zen upgraded shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Truist Financial reissued a “hold” rating and issued a $13.00 price target (down from $15.00) on shares of Integra LifeSciences in a research report on Monday, November 3rd. Citigroup dropped their price objective on Integra LifeSciences from $12.00 to $11.00 and set a “sell” rating on the stock in a report on Friday, October 31st. Finally, JPMorgan Chase & Co. lifted their target price on Integra LifeSciences from $12.00 to $13.00 and gave the stock an “underweight” rating in a research report on Friday, October 31st. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Reduce” and an average target price of $15.00.

Integra LifeSciences Trading Down 2.2%

The business’s 50 day simple moving average is $11.99 and its 200 day simple moving average is $13.20. The company has a debt-to-equity ratio of 1.73, a current ratio of 3.14 and a quick ratio of 1.80. The company has a market capitalization of $882.49 million, a price-to-earnings ratio of -1.75 and a beta of 1.04.

Integra LifeSciences (NASDAQ:IART) last announced its earnings results on Thursday, February 26th. The life sciences company reported $0.83 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.04. The business had revenue of $434.93 million during the quarter, compared to the consensus estimate of $429.62 million. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 14.06%. The business’s quarterly revenue was down 1.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.97 earnings per share. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. Research analysts anticipate that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current year.

Institutional Investors Weigh In On Integra LifeSciences

Several large investors have recently modified their holdings of the stock. Global Retirement Partners LLC acquired a new stake in shares of Integra LifeSciences during the fourth quarter worth $25,000. GAMMA Investing LLC lifted its stake in shares of Integra LifeSciences by 55.3% in the 3rd quarter. GAMMA Investing LLC now owns 2,565 shares of the life sciences company’s stock worth $37,000 after acquiring an additional 913 shares during the period. Osaic Holdings Inc. boosted its holdings in shares of Integra LifeSciences by 36.6% in the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after acquiring an additional 1,104 shares in the last quarter. AlphaQuest LLC acquired a new position in shares of Integra LifeSciences during the second quarter worth about $73,000. Finally, EMC Capital Management purchased a new position in Integra LifeSciences during the second quarter worth about $75,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.